Codexis Inc (CDXS) - Total Liabilities
Based on the latest financial reports, Codexis Inc (CDXS) has total liabilities worth $85.42 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Codexis Inc to see how much of total assets are deployed in long-term investments.
Codexis Inc - Total Liabilities Trend (2006–2024)
This chart illustrates how Codexis Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Codexis Inc's balance sheet.
Codexis Inc Competitors by Total Liabilities
The table below lists competitors of Codexis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
51Talk Online Education Group
NYSE MKT:COE
|
USA | $97.35 Million |
|
AptaBio Therapeutics Inc
KQ:293780
|
Korea | ₩22.51 Billion |
|
Century Land Joint Stock Company
VN:CRE
|
Vietnam | ₫1.43 Trillion |
|
Coda Octopus Group Inc
NASDAQ:CODA
|
USA | $5.92 Million |
|
Odlewnie Polskie SA
WAR:ODL
|
Poland | zł62.72 Million |
|
PYRUM INNOV.AG NA O.N.
F:PYR
|
Germany | €42.95 Million |
|
Keyrus SA
PA:ALKEY
|
France | €264.99 Million |
|
China Electric Manufacturing Corp
TW:1611
|
Taiwan | NT$1.28 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Codexis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CDXS equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Codexis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Codexis Inc (2006–2024)
The table below shows the annual total liabilities of Codexis Inc from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.08 Million | +64.35% |
| 2023-12-31 | $49.95 Million | -52.70% |
| 2022-12-31 | $105.60 Million | +28.79% |
| 2021-12-31 | $81.99 Million | +59.07% |
| 2020-12-31 | $51.54 Million | +18.34% |
| 2019-12-31 | $43.56 Million | +98.19% |
| 2018-12-31 | $21.98 Million | -24.42% |
| 2017-12-31 | $29.08 Million | +75.71% |
| 2016-12-31 | $16.55 Million | -23.98% |
| 2015-12-31 | $21.77 Million | -0.20% |
| 2014-12-31 | $21.81 Million | +25.66% |
| 2013-12-31 | $17.36 Million | -19.36% |
| 2012-12-31 | $21.52 Million | -35.23% |
| 2011-12-31 | $33.23 Million | -2.08% |
| 2010-12-31 | $33.94 Million | -45.44% |
| 2009-12-31 | $62.20 Million | -68.90% |
| 2008-12-31 | $200.01 Million | -0.50% |
| 2007-12-31 | $201.01 Million | +102.17% |
| 2006-12-31 | $99.42 Million | -- |
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more